TRIP13 is upregulated in aggressive chromophobe renal cell carcinoma and may be a promising therapeutic target
IKCS-NA 2025
Elizabeth Ellis, Nathan Maulding, Keiko Akagi, Zhiyuan Yu, Menuka Karki, Nicholas Scott, Pedro Pesquera, Jing Qian, Fei Duan, Abha Grover, Kyle Beauchamp, Kaveh Karbasi, Kanishka Sircar, Luisa Maren Solis Soto, Xinyue Chen, Andrew Sedgewick, Justin Guinney, Jose Karam, Pavlos Msaouel, Niki Zacharias
Abstract
Chromophobe renal cell carcinoma (chRCC) with sarcomatoid features is one of the most lethal renal malignancies. We identified a protein critical to the metastatic potential of chRCC. We describe our experience in preclinical models inhibiting this protein, TRIP13.
Targeted DNA profiling, whole transcriptome gene expression and de-identified clinical data from 168 chRCC samples were collected. Whole-exome and RNA sequencing were performed in a sarcomatoid chRCC tumor and corresponding patient-derived xenograft (RCC251). TRIP13 expression was determined using immunohistochemistry. We performed knockdown of TRIP13 (KD) in UOK276 cells using lentiviral transfection using a vector corresponding to 3 siRNAs against TRIP13 and scramble vector as a control (SC). Scratch, 24-hour invasion, and clonogenic assays were performed in triplicate on stably transfected cells. Wildtype UOK276 cells were injected subcutaneously into NSG mice. Mice were treated with TRIP13 inhibitor DCZ0415 25 mg/kg IP thrice weekly (n = 8) or vehicle (n = 7). TP53 mutations were found in 76 of 168 chRCC patient samples (45%). TP53 mutants had higher expression of TRIP13 than TP53 WT tumors (p < 1 x 10-10). Transcript expression of TRIP13 was 8-fold higher in PDX tumor compared to the original patient’s normal kidney and non-sarcomatoid regions. TRIP13 was enriched in samples that had ≥6 copy-neutral-loss-of-heterozygosity (cnLOH) events compared to those with <6 cnLOH events (p < 1 × 10-5). Cell proliferation, migration, and invasion were reduced in TRIP13 KD cells compared to SC. Reduced tumor growth (p < 0.0001) and tumor mass (p = 0.005) was observed in tumor-bearing UOK276 mice treated with the TRIP13 inhibitor DCZ0415 compared to vehicle.
TRIP13 is upregulated in preclinical models of sarcomatoid chRCC and patient tumors. TRIP13 inhibition reduced tumor growth in a sarcomatoid chRCC animal model. TRIP13 may be a promising therapeutic target in aggressive sarcomatoid chRCC meriting further investigation.
Related publications